Michael Ulz
Stock Analyst at Baird
(4.2)
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
KPTI Karyopharm Therapeut... | Maintains: Outperform | 42 25 | 6.5 | 284.62% | 7 | Aug 12, 2025 | |
ALNY Alnylam Pharmaceutic... | Maintains: Equal-Weight | 312 405 | 458.85 | -11.74% | 11 | Aug 1, 2025 | |
IONS Ionis Pharmaceutical... | Upgrades: Overweight | 55 62 | 62.64 | -1.02% | 5 | Jul 31, 2025 | |
SLN Silence Therapeutics | Maintains: Overweight | 45 25 | 5.31 | 370.81% | 12 | May 9, 2025 | |
VKTX Viking Therapeutics | Maintains: Overweight | 105 102 | 25.01 | 307.84% | 3 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 40 20 | 3.85 | 419.48% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 30 22 | 1.66 | 1225.3% | 6 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 29 | 8.03 | 261.15% | 1 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 11 7 | 8.59 | -18.51% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 24 20 | 2.36 | 747.46% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 20 5 | 5.38 | -7.06% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 18 10 | 0.94 | 963.83% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 46 96 | 43.85 | 118.93% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 48 52 | 13.16 | 295.14% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 110 115 | 129.46 | -11.17% | 9 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 53 57 | 75.68 | -24.68% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 36 27 | 27.52 | -1.89% | 4 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 47 65 | 64.97 | 0.05% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 3 7 | 0.96 | 629.17% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 23 12 | 9.81 | 17.23% | 4 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 15 27 | 10.45 | 158.37% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 42 37 | 58.7 | -36.97% | 9 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 35 40 | 39.95 | 0.13% | 4 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 30 20 | 1.33 | 1403.76% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 45 | 3.13 | 1337.7% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 20 10 | 0.74 | 1251.35% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 6 8 | n/a | n/a | 5 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 3 | 3.23 | -7.12% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Equal-Weight | 18 30 | 5.07 | 491.72% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 135 90 | 116.3 | -22.61% | 3 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 15 7 | 1.88 | 272.34% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 25 30 | 1.27 | 2262.2% | 3 | Mar 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | n/a | n/a | n/a | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 84 36 | 1.4 | 2471.43% | 2 | Jan 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 45 | 10.15 | 343.35% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 500 | 3.49 | 14226.65% | 1 | Sep 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 300 500 | 6.99 | 7053.08% | 2 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 30 | n/a | n/a | 1 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 3 1 | n/a | n/a | 4 | Mar 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 7 4 | 15.14 | -73.58% | 3 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 17 0 | n/a | n/a | 2 | Sep 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 680 544 | n/a | n/a | 2 | Jun 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 85 80 | 31.32 | 155.43% | 2 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 12 15 | 7.87 | 90.6% | 3 | Jul 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 127 182 | n/a | n/a | 2 | Feb 27, 2017 |